| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626 | BioCryst Pharmaceuticals | Phase 2, Phase 3 | Completed | 2016-01Actual |
| Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673 | RYTM | Phase 2 | Completed | 2016-10-26Actual |
| Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromeNCT02352896 | PTC Therapeutics | Phase 2 | Completed | 2023-10-30Actual |
| An Extension of Protocol PRO 140_CD01 StudyNCT02355184 | CytoDyn, Inc. | Phase 2 | Terminated | 2022-06Actual |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579 | IOVA | Phase 2 | Completed | 2024-10-24Actual |
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927 | KURA | Phase 2 | Completed | 2020-12-14Actual |
| Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsNCT02421679 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2016-05-26Actual |
| A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaNCT02436096 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2016-09Actual |
| CardiAMP™ Cell Therapy for Heart Failure TrialNCT02438306 | BCDA | Phase 3 | Completed | 2025-02Actual |
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093 | CADL | Phase 2 | Unknown | 2025-12Estimated |
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228 | KURA | Phase 2 | Completed | 2021-03-31Actual |
| QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)NCT02465957 | IBRX | Phase 2 | Terminated | 2018-03-19Actual |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatNCT02474589 | SIGA Technologies | Phase 3 | Completed | 2016-08-24Actual |
| A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyNCT02476916 | AGIO | Phase 2 | Completed | 2017-05-08Actual |
| A Study With SAGE-547 for Super-Refractory Status EpilepticusNCT02477618 | SUPN | Phase 3 | Completed | 2017-07-18Actual |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 | MacroGenics | Phase 3 | Completed | 2021-08-11Actual |
| Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02500316 | OPK | Phase 2 | Completed | 2023-11Actual |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018 | LSTA | Phase 2 | Completed | 2022-05-19Actual |
| Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisNCT02503657 | MediciNova | Phase 2 | Completed | 2020-12-07Actual |
| Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2023-04-17Actual |
| A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantNCT02540330 | ATOS | Phase 2 | Terminated | 2020-08-13Actual |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095 | VKTX | Phase 2 | Completed | 2017-11-15Actual |
| A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisNCT02578914 | ALDX | Phase 2 | Completed | 2015-12Actual |
| A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsNCT02589275 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2016-09-28Actual |
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862 | AKARI Therapeutics | Phase 2 | Completed | 2018-03-20Actual |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)NCT02598661 | Geron Corporation | Phase 2, Phase 3 | Active not recruiting | 2023-10-13Actual |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionNCT02604199 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2017-01Actual |
| A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
Trial details
- Registry ID
- NCT02303626
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02311673
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02352896
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02355184
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02360579
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02383927
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02421679
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02436096
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02438306
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02446093
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02452528
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02464228
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02465957
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02474589
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02476916
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02477618
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02492711
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02500316
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02501018
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02503657
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02525692
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02540330
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02577029
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02578095
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02578914
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02589275
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02591862
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02598661
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02604199
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02604212
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.